Center for Carcinoid and Neuroendocrine Tumors
We are proud to announce the new multidisciplinary Center for Carcinoid and Neuroendocrine Tumors at The Mount Sinai Hospital. Neuroendocrine tumors (NETs) are a rare form of cancer, and most physicians do not have familiarity with this disease. There are only a few centers in the United States with extensive specialized experience sufficient to be qualified as a center specializing in this field.
Our goal is to provide our patients with a multidisciplinary approach comprised of experts in Surgery, Nuclear Medicine, Cardiology, Pulmonology, Oncology, Hematology, Radiology, Pathology, Gastroenterology, Endocrinology and Nutrition. All physicians in this group have extensive knowledge in the diagnosis and treatment of NET disorders. Patients who come to our center will have the benefit of an expert comprehensive evaluation and treatment of this rare form of cancer. Our treatment pathways have resulted in superior outcomes and survival.
What Are Neuroendocrine Tumors?
There exists a group of relatively rare tumors, called carcinoid and related neuroendocrine tumors, which can affect your health either by secreting chemicals which can cause intense flushing, diarrhea, uncontrolled high blood pressure, behavioral changes, severe stomach ulcers or skin rash, and either diabetes or very low levels of blood sugar. Many of these tumors do not produce an excess of any chemicals but cause symptoms by their growth impinging on normal tissues.
This tumor growth and development is formed by overgrowth of one type of cell: which can be malignant. If this overgrowth is somewhat limited and does not spread to other areas or threaten to squeeze out or replace adjacent structures, it is considered to be a benign tumor, which means it is not life threatening.
However, if the growth is more aggressive and threatens surrounding tissues or sends “seedlings” (metastases) to grow in distant areas then it has potential to be fatal and is considered malignant; that means it is a cancer.
The presence of such tumors is detected on the basis of the patient’s symptoms, and special laboratory blood tests. Radiological tests such as X-rays, CT scans, MRI, ultrasound and isotope can often detect these tumors.
Surgical Treatment Options
At present the only cure for a carcinoid or any other NET is the removal of the entire tumor and any spread by surgery. However, even when this is not possible, surgery can often remove critically situated tumor tissue which can relieve symptoms and prolong quality of life.
Medical Treatment Options
When surgery is not possible or only partially effective, a wide variety of medical treatments are available to further relieve symptoms, and extend quality of life. These include hormonal drugs, radiation, isotopes and various types of targeted personalized chemotherapies. NETs have been called “cancers in slow motion” because even though they usually have the potential for ultimately being fatal, they mostly tend to grow so slowly that people afflicted with these tumors usually live for many years, indeed sometimes for a normal life time. The wide variety of treatment now available makes the outlook for most patients with the more aggressive carcinoids and other NETs more hopeful than it used to be. Here at The Mount Sinai’s Center for Carcinoid and Neuroendocrine Tumors, our team will thoroughly evaluate your case and provide the treatment options that are most fitting for you.
Did You Know?
- Over 90% of all carcinoid/ NETs are incorrectly diagnosed and treated for the wrong disease
- From initial onset of symptoms the average time to proper diagnosis exceeds five years
- More than 12,000 new cases of carcinoid/ NETs are diagnosed each year
- Physicians are often not aware of current diagnostic and treatment options
- Many physicians still believe that carcinoid tumors are benign, slow growing and do not metastasize
- Irritable Bowel Syndrome (IBS) and Crohn’s disease are the two most common misdiagnosed conditions for patients with midgut carcinoid
- Abdominal pain, flusing, diarrhea, wheezing, bloating, heart palpitation, weakness, skin rash, heartburn and weight changes are the most prevalent carcinoid/ NET symptoms
- At least 125,000 people are living with carcinoid/ NETs in the United States
Richard R. P. Warner, MD
Director, Center for Carcinoid and NeuroEndocrine Tumors
Professor of Medicine
Celia M. Divino, MD
Professor and Chief of General Surgery
Steven D. Herman, MD
Adjunct Clinical Associate
Professor of Cardiothoracic Surgery
William B. Inabnet III, MD
Professor of Surgery
Andrew Kaufman, MD
Assistant Professor of Cardiothoracic Surgery
Michelle K. Kim, MD
Assistant Professor of Gastroenterology
Josef Machac, MD
Director of Nuclear Medicine
Professor of Radiology and Medicine
Lynn H. Ratner, MD
Assistant Clinical Professor of Hematology and Medical Oncology
Sasan Roayaie, MD
Associate Professor of Surgery
Associate Professor of Liver Diseases
Michail Shafir, MD
Clinical Professor of Surgery and Surgical Oncology
Max W. Sung, MD
Associate Professor of Hematology and Medical Oncology
Jerome S. Zacks, MD
Assistant Clinical Professor of Cardiology
To Learn More
Please call us with any questions you may have, and we will be happy to set up an appointment with one of our experienced and dedicated Carcinoid and Neuroendocrine Experts. Call us at 212-796-8640 to set up an appointment.
The Mount Sinai Health System
Center for Carcinoid and Neuroendocrine Tumors
One Gustave L. Levy Place
New York, NY 10029
Out of nearly 5,000 hospitals evaluated, the Mount Sinai Health System ranks #9 in the nation for Digestive Disease in the 2013-2014 "Best Hospitals" issue of U.S. News & World Report. Learn More